The phrase “drug-resistant bacteria” can flatten several different problems into one frightening label. Europe’s newest surveillance warning is more specific — and more operationally useful.
In its Week 40 Communicable Disease Threats Report, ECDC says the epidemiological situation involving carbapenem-resistant Enterobacterales is worsening rapidly across the EU and European Economic Area. New findings come from the CRE25 genomic survey and multi-country investigations conducted through the European Antimicrobial Resistance Genes Surveillance Network (ECDC Week 40 report).
Carbapenems are antibiotics commonly reserved for serious infections caused by bacteria resistant to other treatments. Enterobacterales include organisms such as Klebsiella pneumoniae and Escherichia coli. Resistance in this group is especially consequential because these bacteria can cause bloodstream, urinary-tract and respiratory infections, including in healthcare settings and medically vulnerable patients.
ECDC identifies several changes occurring at once.
First, a growing proportion of carbapenem-resistant K. pneumoniae isolates carry NDM carbapenemases — enzymes that can disable a broad range of beta-lactam antibiotics. ECDC notes that this resistance includes several combinations introduced in Europe during the last decade specifically to treat carbapenem-resistant infections.
Second, resistance and virulence genes are increasingly appearing together. Virulence refers to characteristics that help a bacterium cause disease. ECDC reports more K. pneumoniae carrying genes associated with iron-acquisition systems such as yersiniabactin and aerobactin. A strain that is difficult to treat is one problem. A strain that is both difficult to treat and better equipped to cause infection is a more dangerous convergence.
Third, some of the genetic vehicles carrying these traits are moving across borders. ECDC describes mosaic plasmids carrying carbapenemase and virulence genes, and says patient transfers, referral networks and mobility can support rapid healthcare-associated spread. It also reports emerging K. pneumoniae sequence types, including ST6668, reaching several countries.
The warning is not limited to hospitals or Klebsiella. ECDC also notes wider detection of E. coli carrying carbapenemase genes such as blaOXA-244, including evidence of spread in community settings. That changes the surveillance problem: health systems need to detect both institutional transmission and organisms appearing beyond the hospital environment.
Genomic surveillance is central because routine susceptibility testing can show that an isolate is resistant, while sequencing can reveal which genes, plasmids and bacterial lineages are moving between facilities or countries. That can help investigators distinguish isolated cases from linked transmission and identify routes that ordinary case totals may miss.
The report does not provide a single Europe-wide patient count for this development, and it should not be translated into one. Isolate proportions, genomic clusters, infections and colonization are different measures. Some people carry resistant organisms without clinical infection, while others develop severe disease.
What is fact: the resistance genes, virulence markers, sequence types and cross-border patterns identified by ECDC.
What is analysis: the conclusion that laboratory networks, patient-transfer communication and infection prevention must be treated as one connected control system.
What remains uncertain: the eventual clinical burden, how widely particular lineages have spread and what ECDC’s forthcoming updated risk assessment will recommend.
“Superbug” is an attention-grabbing word. The more important story is the infrastructure required to see resistance moving — and interrupt it before a difficult pattern becomes routine.
Persona disclosure. Dex Mercer is a recurring fictional TiPH editorial persona. His work is researched and edited under Today in Public Health’s editorial standards; he is not a real-world correspondent or quoted source.
Related on TiPH: Global Signal Scan, October 4, 2026 · Latest news · How we verify signals